MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush

MBX Biosciences has filed for an initial public offering (IPO) on the NASDAQ, aiming to raise $100 million.
The company is the third biotech to file for a NASDAQ listing within a two-day period, following Bicara Therapeutics and Zenas Biopharma.
MBX Biosciences plans to use the IPO proceeds to advance its lead program MBX 2109 through Phase II and into Phase III studies for chronic hypoparathyroidism.
The company will also allocate funds to support its investigational GLP-1 receptor antagonist MBX 1416 and preclinical candidate MBX 4291 for obesity.
MBX Biosciences recently closed a $63.5 million Series C financing round, which will help sustain the biotech into 2026.